Lexeo CFO sells shares to cover RSU taxes

Lexeo Therapeutics’ Chief Financial Officer Louis Edward Tamayo reported a mix of stock grant and related share sale.

Rhea-AI Filing Summary

Lexeo Therapeutics’ Chief Financial Officer Louis Edward Tamayo reported a mix of stock grant and related share sale. On June 29, 2026, he received an award of 12,000 shares of common stock at no cost as compensation.

On July 1, 2026, he sold 4,641 shares of common stock at a weighted average price of $4.49 per share. A footnote explains this sale was made to cover tax obligations on the release of performance Restricted Stock Units (RSUs), meaning it was a tax-related disposition rather than a discretionary portfolio sale.

Following these transactions, he directly holds 97,024 shares of common stock, which include 89,665 RSUs. Each RSU represents a contingent right to receive one share of Lexeo common stock in the future, typically upon meeting vesting conditions.

Insider Trade Summary

Net Seller: 4,641 shares

Net Sell 2 txns

Insider Tamayo Louis Edward

Role Chief Financial Officer

Sold 4,641 shs ($21K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,641	$4.49	$21K
Grant/Award	Common Stock	12,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 97,024 shares (Direct)

Footnotes (3)

1. F1. Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").
2. F2. This transaction was executed in multiple trades at prices ranging from $4.33 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. Includes 89,665 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

Key Figures

Shares sold: 4,641 shares Sale price: $4.49 per share Shares granted: 12,000 shares +2 more

5 metrics

Shares sold 4,641 shares Open-market sale on July 1, 2026

Sale price $4.49 per share Weighted average sale price

Shares granted 12,000 shares Stock award on June 29, 2026

Shares held after 97,024 shares Direct holdings after reported transactions

RSUs included 89,665 RSUs Part of post-transaction direct holdings

Key Terms

Restricted Stock Units ("RSUs"), weighted average sale price, contingent right, grant, award, or other acquisition

4 terms

Restricted Stock Units ("RSUs") financial

"Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

contingent right financial

"Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."

grant, award, or other acquisition financial

"Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Lexeo (LXEO) report for its CFO?

Lexeo’s CFO Louis Edward Tamayo received 12,000 common shares as a stock award and sold 4,641 shares. The sale was reported as an open-market transaction mainly to satisfy tax obligations tied to performance RSU vesting.

How many Lexeo (LXEO) shares did the CFO sell and at what price?

The CFO sold 4,641 shares of Lexeo common stock at a weighted average price of $4.49 per share. Trades occurred between $4.33 and $4.73, with the reported figure reflecting the weighted average sale price.

Why did the Lexeo (LXEO) CFO sell shares in this Form 4 filing?

The filing states the sale was to cover tax obligations on the release of performance RSUs. This indicates the disposition was tax-related, linked to equity vesting, rather than a discretionary decision to reduce overall exposure to Lexeo shares.

How many Lexeo (LXEO) shares does the CFO hold after these transactions?

After the reported award and sale, the CFO directly holds 97,024 Lexeo common shares. This total includes 89,665 Restricted Stock Units, each representing a contingent right to receive one share upon satisfaction of vesting conditions.

What RSU information did the Lexeo (LXEO) Form 4 disclose for the CFO?

The Form 4 notes that the CFO’s holdings include 89,665 Restricted Stock Units. Each RSU is described as a contingent right to receive one share of Lexeo common stock, typically dependent on meeting specified performance or service-based vesting requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 06:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tamayo Louis Edward

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		A		12,000	A	$0	101,665	D
Common Stock	07/01/2026		S(1)		4,641	D	$4.49(2)	97,024(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $4.33 to $4.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 89,665 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

	/s/ Youjin Choi, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)